Endpoint International Index of Erectile Function (IIEF) total scores (The IIEF is a self‐report measure with 15 questions examining erectile function, orgasmic function, sexual desire, and intercourse satisfaction. Maximum possible score 75) · people with antidepressant‐induced sexual dysfunction
1 finding from 1 review
Endpoint International Index of Erectile Function (IIEF) scores ‐ question 3: ability to achieve erection (Maximum score 5) · people with antidepressant‐induced sexual dysfunction
1 finding from 1 review
Endpoint International Index of Erectile Function (IIEF) scores ‐ intercourse satisfaction (questions 6, 7, 8) (Maximum score 15) · people with antidepressant‐induced sexual dysfunction
1 finding from 1 review
Dropout · people with antidepressant‐induced sexual dysfunction
Sildenafil showed no clear difference in dropouts (People leaving the trial early) compared with placebo (high certainty).
1 finding from 1 review
Global Efficacy Questionnaire (questions 1 & 2) (Questions assessing improvement attributed to medication compared to having no treatment at all) · people with antidepressant‐induced sexual dysfunction
Sildenafil probably leads to higher global Efficacy Questionnaire (questions 1 & 2) (Questions assessing… compared with placebo (moderate certainty).
1 finding from 1 review
Effect on later sexual function · people with antidepressant‐induced sexual dysfunction
Bupropion showed no clear difference in 50% reduction in score on the Arizona Sexual Experiences Scale… compared with placebo (moderate certainty).
1 finding from 1 review
Dropout · people with antidepressant‐induced sexual dysfunction
Bupropion showed no clear difference in dropouts (People leaving the trial early) compared with placebo (high certainty).
1 finding from 1 review
Failure to respond (reduction ≥ 50% on HDRS) · patients with depression
Fluoxetine showed no clear difference in failure to respond (reduction ≥ 50% on HDRS) compared with TCAs (moderate certainty).
1 finding from 1 review
Failure to complete ‐ side effects ‐ · patients with depression
Fluoxetine may leads to lower failure to complete ‐ side effects ‐ compared with ABT‐200 (low certainty).
1 finding from 1 review
Failure to complete ‐ side effects ‐ · patients with depression
It is very uncertain whether fluoxetine changes failure to complete ‐ side effects ‐ compared with phenelzine (very low certainty).
1 finding from 1 review
Failure to respond (reduction ≥ 50% on HDRS) · patients with depression
Fluoxetine showed no clear difference in failure to respond (reduction ≥ 50% on HDRS) compared with pramipexole (low certainty).
1 finding from 1 review
Endpoint score (HDRS or MADRS) · patients with depression
1 finding from 1 review
Failure to complete ‐ total ‐ · patients with depression
Fluoxetine may leads to lower failure to complete ‐ total ‐ compared with pramipexole (low certainty).
1 finding from 1 review
Failure to complete ‐ inefficacy ‐ · patients with depression
Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with pramipexole (low certainty).
1 finding from 1 review
Failure to complete ‐ side effects ‐ · patients with depression
Fluoxetine may leads to lower failure to complete ‐ side effects ‐ compared with pramipexole (low certainty).
1 finding from 1 review
Failure to respond (reduction ≥ 50% on HDRS) · patients with depression
Fluoxetine showed no clear difference in failure to respond (reduction ≥ 50% on HDRS) compared with reboxetine (moderate certainty).
1 finding from 1 review
Endpoint score (HDRS or MADRS) · patients with depression
1 finding from 1 review
Failure to complete ‐ total ‐ · patients with depression
Fluoxetine probably leads to lower failure to complete ‐ total ‐ compared with reboxetine (moderate certainty).
1 finding from 1 review
Failure to complete ‐ inefficacy ‐ · patients with depression
Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with reboxetine (moderate certainty).
1 finding from 1 review
Failure to respond (reduction ≥ 50% on HDRS) · patients with depression
Fluoxetine showed no clear difference in failure to respond (reduction ≥ 50% on HDRS) compared with agomelatine (low certainty).
1 finding from 1 review